UM: Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

UM: Phase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment

An international phase III clinical trial evaluating the drug Arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) has reached full enrollment, as reported by a University of Miami Miller School of Medicine researcher. The current phase III trial builds upon the results of a prior phase II trial that enrolled patients with a rapidly progressive, rare genetic form of ALS.

Full Story

Related posts

UNF physics lecturer receives U.S. Patent

Nirmalkumar Patel, a University of North Florida physics associate lecturer, received a U.S. Patent for…

UNF professor reports on returning to exercise post-pandemic, staying healthy in the new year

Dr. James Churilla, UNF professor and Exercise Science and Chronic Disease Graduate Program director, recently…

FIT Biochemist Studies Farming on Mars

Farming on Mars will be a lot harder than ‘The Martian’ made it seem.  Growing…